Updates and future perspectives on neuropsychiatric symptoms in Alzheimer's disease
Alzheimer's & Dementia · 2025-03 · 21 (3)
DOI: 10.1002/alz.70079 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia, online erschienen am 27.03.2025. Verfasst von Myuri Ruthirakuhan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Alzheimer Disease, COVID-19. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Neuropsychiatric symptoms (NPS) are common throughout the Alzheimer's disease (AD) continuum and profoundly affect patients, caregivers, and health‐care systems. This review synthesizes key research presented in the 2022 and 2023 Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment Neuropsychiatric Syndromes–Professional Interest Area (NPS‐PIA) Year‐In‐Reviews, emphasizing six critical areas: (1) diversity and disparities, (2) diagnostic frameworks, (3) neurobiology of NPS, (4) NPS as a disease marker, (5) the impact of COVID‐19, and (6) interventions. NPS accelerates AD progression, increases functional decline, diminishes quality of life, and heightens caregiver burden and institutionalization rates. Current treatments primarily rely on psychotropics, which offer limited efficacy and raise safety concerns. This review aims to inform clinicians and researchers about recent NPS advancements while identifying gaps for future studies to improve outcomes for individuals with AD. Highlights Research in Alzheimer's disease–related neuropsychiatric symptoms has rapidly increased, indicating heightened interest. Key areas include: diversity, diagnostics, markers, COVID‐19 impact, and treatments. A road map for future studies, based on the key areas of research, is provided. This road map includes considerations to improve study applicability and validity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
- Cummings School of Medicine, and Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
- UNSW Ageing Futures Institute, University of New South Wales, Kensington, New South Wales, Australia.
- Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
- Institute of Public Health, Washington University, St. Louis, Missouri, USA.
ORCID-Profile: Myuri Ruthirakuhan
Zitieren
APA
Ruthirakuhan, M., Guan, D. X., Mortby, M., Gatchel, J., & Babulal, G. M. (2025). Updates and future perspectives on neuropsychiatric symptoms in Alzheimer's disease. Alzheimer's & Dementia, 21(3). https://doi.org/10.1002/alz.70079
Vancouver
Ruthirakuhan M, Guan DX, Mortby M, Gatchel J, Babulal GM. Updates and future perspectives on neuropsychiatric symptoms in Alzheimer's disease. Alzheimer's & Dementia. 2025;21(3). doi:10.1002/alz.70079
BibTeX
@article{Ruthirakuhan2025,
author = {Ruthirakuhan, Myuri and Guan, Dylan X and Mortby, Moyra and Gatchel, Jennifer and Babulal, Ganesh M},
title = {Updates and future perspectives on neuropsychiatric symptoms in Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {3},
doi = {10.1002/alz.70079}
}
EUVIMED